A novel role of the splenic volume in Crohn’s disease: evaluating the efficacy of infliximab

ABSTRACT: Background: A number of patients with Crohn’s disease (CD) suffer from loss of response to infliximab (IFX) therapy. Splenic volume is reported to be enlarged in patients with CD compared to normal individuals. The association between splenic volume and IFX efficacy in CD remains unclear. Methods: We performed a retrospective study of patients with CD who received regular IFX treatment at Zhongshan Hospital, Fudan University, between August 2015 and December 2021. We collected baseline characteristics and clinical features from medical records in the CD database of Zhongshan Hospital. We accurately measured the splenic volume using semi-auto spleen segmentation software, followed by the analysis of splenic volume and IFX efficacy. Results: We included 49 patients with CD receiving IFX trea

SUBMITTER: Shi X 

PROVIDER: S-EPMC10470019 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature